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Abstract
Pain is one of the most frequent complaints reported by cancer patients. In their terminal periods, the
proportion of patients suffering from pain reaches 75%. Even, the most convenient route of administration of
medicines is the oral route, not every clinical situation permits the oral therapy. Alternative routes of
administration of medicines, especially in palliative medicine, involve multiple injections or continuous
infusions, both subcutaneous and intravenous. Most opioids (morphine, diamorphine in small doses, oxycodon,
pethidine, fentanyl, tramadol) can be administered subcutaneously. There are no significant differences
between the subcutaneous and intravenous (i.v.) application of medicines in terms of their absorption,
efficacy and the frequency of side effects. The titration of i.v. opioids is not only an effective and rapid
method of pain relief, but also is safe and unrelated to increased risk of respiratory centre depression. The
role of intravenous administration of medicines increase especially at the terminal stages of cancer patients’
life. An appropriate choice of administration route or its exchange to an alternative one may in a number of
cases improve the comfort and quality of life of patients receiving palliative care.
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Introduction
Pain is one of the most frequent complaints re-
ported by cancer patients. The number of cancer
patients constantly increases [1]. Each year, about 9
million new cases are reported, and it is expected
that in the year 2030 the number will exceed 15
million [2]. The incidence and intensity of pain is
associated with the type of the underlying disease
and its stage. In their terminal periods, in patients
receiving palliative care, the proportion of patients
suffering from pain reaches 75% [3].
At present, the strategy of treatment of cancer
pain is primarily based on the three-step analgesic
ladder formulated in 1986 [4]. Thanks to its practi-
cal application, it is possible to control pain in 85–
90% patients. The most important element of WHO
guidelines and a major reason for the effectiveness
of treatment is the use of opioid medicines to con-
trol moderate to severe pain. Despite the existence
of a number of new strong synthetic opioids, mor-
phine is still the most popular medicine from the
third step of the analgesic ladder and still consti-
tutes the golden standard of pain treatment.
The most convenient route of administration of
medicines is the oral route. It is the most natural
manner of administration, which does not cause
additional discomfort or pain to patients.
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However, not every clinical situation permits the
oral therapy. There are certain contraindications and
factors that limit this route of administration, in-
cluding the following [5]:
— serious fatigue, which makes it impossible for
patients to receive medication orally;
— the need for continuous pain control in uncon-
scious patients;
— persistent nausea and vomiting;
— obstruction of the gastrointestinal tract;
— dysphagia or swallowing difficulties;
— impaired laryngeal reflex;
— gastrointestinal absorption disorders involving
medicines;
— the need for fast treatment of severe pain;
— on request of the patient who would otherwise
have to swallow a lot of pills.
The oral route may also prove less than optimal
in the context of impaired bioavailability after such
administration, such as:
— for some medicines, limited transport through
the intestinal mucous membrane;
— interaction of foods with medicines;
— metabolic inactivation by the mucous membrane
and the intestinal flora;
— metabolic inactivation by the liver (the so-called
first-pass effect) [5].
Alternative routes of administration of medicines,
especially in palliative medicine, involve multiple in-
jections or continuous infusions, both subcutane-
ous and intravenous.
Subcutaneous administration
of medicines
The history of subcutaneous administration of
morphine dates back to the American Civil War,
with the first subcutaneous (s.c.) injections to in-
jected soldiers having been made in 1863. After
over a hundred years, since 1979 s.c. infusions of
morphine have been used in the treatment of can-
cer pain. At present, this is one of the most often
used administration routes for medicines in pallia-
tive medicine.
Most opioids can be administered subcutane-
ously. The class includes: morphine, diamorphine
(in small doses), oxycodon, pethidine, fentanyl, tra-
madol [6–8]. Subcutaneous administration of meth-
adone is usually avoided owing to strong cutane-
ous response at injection sites. However, there are
reports suggesting that with the application of the
hypodermoclysis line, local cutaneous side effects
are considerably smaller [9].
Subcutaneous administration of medicines, both
as injections repeated every 4 hours and as continu-
ous infusion, has a number of significant advanta-
ges. They involve:
— the possibility to administer small volumes for a
long time;
— efficient absorption;
— lesser discomfort caused by tissue stretching
— considerably smaller than the pain accom-
panying intramuscular or intravenous injec-
tions;
— the possibility to administer anti-emetic medi-
cines, analgesics, cholinolytics and sedatives
— simultaneous treatment/control of a number
of symptoms (“drug combinations”);
— high surface/volume coefficient;
— simple preparation of medicine mix and conve-
nient operation of the syringe/hypodermatocly-
sis pump (available pumps are usually light-
weight, portable, small or elastomeric);
— significantly reduced incidence of infections;
— stable concentration of medicines in blood se-
rum [5, 10].
In Poland, most often used are single injections
repeated every 4 hours. In some developed coun-
tries, portable, convenient to use, battery-powered
or elastomeric pumps for continuous s.c. infusions
constitute standard procedure in situations that
demand subcutaneous administration of medicines
[11], but in Poland, they are unfortunately still rare-
ly used owing to their cost. One of the minor draw-
backs related to the use of these simple devices is
the need to prepare the infusion drug mix for every
24 hours. This causes problems in changing the dos-
age of medicines. In order to modify the infusion
volume in a given time unit, it is necessary prepare
drug mix in the pump again [5, 12].
Watanabe et al. [13] in a randomised double-
blind trial did not demonstrate statistically signifi-
cant differences in opioid efficacy and the occur-
rence of side-effects after subcutaneous continuous
infusion of opioids vs. divided-dose injections in
patients with stable cancer pain.
Subcutaneous administration of medicines re-
quires that attention should be paid to the type of
needle/cannula. The choice includes short metal but-
terfly needles or teflon-coated cannulae. The latter,
on average, last twice as long as metal needles,
therefore they should be used for subcutaneous in-
fusions in terminally ill patients.
Below, follows an overview of fundamental prin-
ciples governing the location and exchange of s.c.
canulae:
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— the needle/cannula can be placed on the chest,
the abdominal wall or the thigh;
— in agitated patients, it is better to insert the
needle into the patient’s back close to the scap-
ula in order to avoid accidental removal;
— transfusion sets ought to be changed every 24
hours;
— the location of the cannula should be changed
in the event of oedema or the haematoma at
needle insertion site, the presences of blood in
the drain or leakage at needle insertion site;
— the needle insertion site should be routinely
changed every 5–7 days [5].
The duration of needle placement, apart from
the above-mentioned type of cannula, is influenced
by the type of needle/cannula on the pH and osmola-
lity of medicine/medicine mix. Only isotonic solutions
reduce the risk of skin irritations. Such medicines as
e.g. diazepame, prochlorperazine, cause considerable
skin irritation and sterile skin abscesses. Adding 1
mg of dexamethasone or 100 mg hydrocortisone to
the solution/24 hours significantly increases the “sur-
vival time” of indwelling cannulae [5].
Next, the stability and compatibility of the infu-
sion mix are influenced by such factors as its vol-
ume, pH, the temperature in which the mix is pre-
pared, stored and administered, the order of add-
ing individual medicines to the mix and the pres-
ence of preservatives [5].
Although, as already mentioned above, one of
the main advantages of subcutaneous infusions is
the opportunity to simultaneously use several prep-
arations, experience shows that under optimal con-
ditions the infusion should contain as few compo-
nents (i.e. different medicines) as possible and in
lowest possible concentrations. [5].
O’Doherty et al. [14], in their article published in
2001 mention six most frequently administered
medicines in subcutaneous infusions using an auto-
matic syringe: diamorphine, haloperidol, levome-
promazine, cyclizine, midazolam and metoclopra-
mid. Data comes from 165 palliative medicine cen-
tres, from the UK and from Ireland. Most frequent
s.c. drug mixes include:
— 2 medicines: diamorphine + midazolam; diamor-
phine + levomepromazine; diamorphine + ha-
loperidol;
— 3 medicines: diamorphine + cyclizine + halo-
peridol; diamorphine + cyclizine + midazolam;
diamorphine + haloperidol + midazolam.
Palliative medicine specialists surveyed most of-
ten use mixtures of three (52% centres surveyed) or
four different medicines (36% centres surveyed).
Five years later, Wilcock et al. [15] analysed the
medicine mixes administered subcutaneously in
328 automatic syringes during a prospective study
of 15 palliative medicine centres. 44% reported a
mixture of two medicines, whereas 30% reported
three different compounds. Comparing the data
with the earlier survey, one can see a significant
trend to reduce the number of medicines com-
bined.
When analysing the literature concerning sub-
cutaneous analgesic administration, one can find
publications that focus on its drawbacks and limi-
tations. Fonzo-Christe et al. [16] evaluated the use
of subcutaneous medicines in the elderly in geriat-
ric wards. They demonstrated a frequent occurrence
of such adverse events as: pain (88%), inflammato-
ry infiltration (75%) and oedema (51%). Among the
medicines that in over 50% of the centres surveyed
were administered subcutaneously (e.g. morphine,
hydromorphone, haloperidol, levomepromasine,
furosemide, glucopyrronium, dexamethasone), only
morphine and dexamethason were licensed for sub-
cutaneous use in Switzerland. However, some pain
medicines (fentanyl, ketorolac), antimuscarinic and
anti-emetic (glycopyrronium, ondansetron, metoclo-
pramid), antipsychotic (haloperidol) and benzodi-
azepines (clonazepam, midazolam), even though
they are not licensed for subcutaneous use, they are
recommended for s.c. use in palliative medicine by
reference manuals.
Few publications offer data concerning the as-
sessment of stability of medicine mixes and safety
of their use. These are, however, research results
based on small groups. Positive results were ob-
tained with the following combinations of medi-
cines: morphine + midazolam + haloperidol + hyos-
cine [17–19], tramadol + hyoscine [20] and trama-
dol + dexametazon [21]. Great care must be taken,
however, in prescribing these medicines, as there is
a distinct gap in research evaluating the efficacy
and safety of a considerable number of prepara-
tions using the route discussed.
The usefulness of subcutaneous administration
of third-stage analgesic ladder medicines has been
induced in European guidelines Morphine and al-
ternative opioids in cancer pain: the EAPC recom-
mendations of 2001 [22]:
8. If patients are unable to take morphine orally
the preferred alternative route is subcutaneous.
There is generally no indication for giving mor-
phine intramuscularly for chronic cancer pain
because subcutaneous administration is simpler
and less painful. (C)
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The advantages of subcutaneous injection are
as follows:
— a smaller needle is required, the chance of dam-
age to nerves is less so that the site of injection
is not crucial, and the possibility of inadvertent
intravenous injection is less because veins can
be seen more easily.
— multiple or continuous subcutaneous adminis-
tration of a medicine is comfortable and pain-
less thanks to butterfly needle insertion, usually
in the vicinity of the subclavicular region; this
method is less painful for the patient and is con-
siderably cheaper.
— absorption is similar and peak plasma concen-
trations are achieved within 15–30 minutes, with
a more rapid onset of drug action than after oral
morphine administration.
10.In patients requiring continuous parenteral mor-
phine, the preferred method is by subcutaneous
infusion. (C)
Portable battery-operated syringe drivers are now
widely used to administer drugs by continuous slow
infusion to patients with advanced cancer who are
unable to take oral medication.
Subcutaneously administered medicines are ab-
sorbed primarily by capillary diffusion, which makes
it possible to avoid the so-called first-pass effect.
There are no significant differences between the
subcutaneous and intravenous application of med-
icines in terms of their absorption, efficacy and the
frequency of side effects [23]. However, in cachectic
patients and those with disturbed peripheral circu-
lation, the process of absorption can be significant-
ly reduced. Patients tolerate well the subcutaneous
infusion rate of £ 5 ml/hr. Greater volumes are used
for subcutaneous supplementing of liquids in dehy-
drated patients. Subcutaneous infusions should not
located at sites of lymphoedema both because of
limited absorption and increased risk of infection at
the injection site [5].
The subcutaneous route of administration of
medicines can also be used for the so-called Pa-
tient-Controlled s.c. Analgesia (PCA) combined with
continuous s.c. infusion of an analgesic. This meth-
od is usually used in the case of incidental pains
with large daily differences in pain intensity, in pa-
tients who wish to maintain control over the thera-
py used (high internal locus of control) and in pa-
tients with an “extreme” sense of anxiety of adverse
events (AE). Contraindications to PCA are as fol-
lows: alcoholism, substance addiction, cognitive dis-
orders and the lack of knowledge and experience of
the pain-treatment team [11].
It is necessary, however, to bear in mind that
there exist situations in subcutaneous administra-
tion of medicines is inadvisable or in which continu-
ous infusion may be necessary. European guidelines
Morphine and alternative opioids in cancer pain:
the EAPC recommendations of 2001 suggest that
[22]:
11.Intravenous infusion of morphine may be pre-
ferred in patients:
a. who already have an indwelling intravenous
line,
b. with generalized oedema,
c. who develop erythema, soreness or sterile ab-
scesses with subcutaneous administration,
d. with coagulation disorders,
e. with poor peripheral circulation.
In recent years, in palliative medicine wards, the
number of cancer patients has increased with sub-
cutaneous ports or central vein catheters, which
greatly modifies the therapeutic options and their
efficacy [24].
The intravenous route is also preferable if medi-
cines need to be administered frequently for the
purpose of “fact and effective control” of pain and
other symptoms. Intravenous opioids ensure their
complete absorption and rapid pain relief (10–15
minutes after i.v. morphine administration, 2–5 min-
utes after i.v. methadone administration). Harris et
al. [25] compared the time necessary to achieve
satisfactory degree of severe cancer pain control
from the onset of i.v. vs. oral morphine administra-
tion. The target was reached in 100% of patients
studied after 3 hours from the beginning of i.v.
treatment, and after 11 hours in the oral adminis-
tration group.
In the latest, 2009 edition of the Palliative Me-
dicine manual edited by Bruera E., results of a num-
ber of trials determining the time necessary to ob-
tain relief during morphine titration. In i.v. adminis-
tration, the time of titration was 9.7 to 100 min-
utes, while oral titration the time was longer
— from 1 to 2.3 days [11].
In order to maintain analgesia, it is necessary to
administer frequent (every 4 hours) boluses or con-
tinuous pump infusion. The latter option is prac-
tised considerably more frequently, especially in
hospitalised patients to maintain a stable concen-
tration of medicine in blood and convenience for
the nursing staff as well as avoidance of repeated
painful injections. Continuous intravenous opioid
infusion can be a safe and effective method of pain
control in patients earlier unsuccessfully treated with
maximal tolerated doses of opioid administered by
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a different route. Most often used are short-acting
opioids such as: morphine, hydromorphone and fen-
tanyl [26, 27]. Owing to their short half-life, the risk
of toxic symptoms caused by the accumulation and
increased serum levels is much smaller than in the
case of methadone or levorfanol, which are charac-
terized by considerably longer half life.
Dobrogowski et al. [28] in a recently published
Position on pain treatment in cancer patients pro-
pose the following manner of titration, i.e. a de-
termination of an effective and safe dose of a
strong opioid omitting the 2nd step of the analge-
sic ladder:
— intravenously: 1–2 mg every 5–10 minutes, until
perceptible pain control is achieved (or the emer-
gence of adverse events, such as sedation);
— continuation of treatment: e.g. if the effective
dose obtained via titration was 6 mg, depend-
ing on the clinical condition of the patient, the
following should be applied:
— continuous i.v. or s.c. infusion of 1 mg morphine
per hour (the half-life of morphine is 3–4 the
hours, which means that in this instance, 3 mg
of morphine will biodegrade and must be sup-
plemented in order to maintain the therapeutic
concentration in blood serum; therefore the pa-
tients will need to have 3 mg of morphine sup-
plemented within 3 hours, hence the continu-
ous infusion rate amounts to 1 mg/hr) [24].
After patient titration and determining the ef-
fective dose of medicine, one can:
— continue continuous i.v. infusion;
— change the route of administration to subcuta-
neous or apply single s.c. boluses every 4 hours
(in an identical daily dose as during i.v. infu-
sion);
— change in the route of administration to oral
using the dosage conversion rate of 1:2 or 1:3
[29, 22], e.g. aqueous solution of morphine ev-
ery 4 hours or controlled release tablets admin-
istered every 12 hours. The total daily dosage of
oral preparations is the same (e.g. the patient
who requires 60 mg of morphine per twenty-
four hours can receive 10 mg of aqueous solu-
tion every 4 hours or 2 doses of 30 mg as con-
trolled release tablets).
European guidelines Morphine and alternative
opioids in cancer pain: the EAPC recommendations
recommend the following conversion mode of mor-
phine dosage depending on the administration
route [22]:
12.The average relative potency ratio of oral to in-
travenous morphine is between 1:2 and 1:3.
When changing from the oral to intravenous
preparation, the dose of the oral preparation should
be divided by 3.
The potency and clinical effects of i.v. and s.c.
morphine is the same [22, 23], although according
to some authors, bioavailability of morphine and its
active metabolites — M6G and M3G — is signifi-
cantly higher after i.v. [30] administration.
The titration of i.v. opioids is not only an effec-
tive and rapid method of pain relief, but also is safe
and unrelated to increased risk of respiratory centre
depression [31].
Parenteral administration of opioids may have
additional important advantages, such as:
— no constipation in patients receiving i.v. mor-
phine, which the authors of the study attributed
to the reduced capacity of medicine binding with
opioid receptors in the gastrointestinal tract com-
pared with patients receiving oral opioids [32];
— less frequent nausea and vomiting when using
s.c. or i.v. opioids compared to the oral route
[33–35];
— significant improvement in pain management
quality (using continuous subcutaneous or in-
travenous infusion opioids).
Enting et al. demonstrated significant improve-
ment in pain control after continuous s.c. or i.v.
infusion in 71% cancer pain patients studied, in
whom previously used oral or transcutaneous anal-
gesics were ineffective [36].
Intravenous morphine boluses are an irreplace-
able method of relieving piercing pain, especially in
hospital wards. The effectiveness of this method is
described not only in patients receiving morphine
as basic pain relief medicine (20% of the daily dose
of morphine converted to oral dosage) [37, 38], but
also in patients treated with other opioids, e.g. by
transcutaneous buprenorphine [39].
In Intensive Care Units, where sometimes pa-
tients with very severe, difficult to control cancer
pain are referred, i.v. fentanyl is preferentially used.
The time necessary to obtain the therapeutic effect
is c.a. 11 minutes [27]. After determining the opti-
mal dose of medicine, the intravenous route of ad-
ministration can be switched to transdermal fenta-
nyl using the conversion rate of 1:1 [40].
Patient Controlled Analgesia (PCA) is most often
used during intravenous administration of medi-
cines. Both in adults and in children, intravenous
morphine or fentanyl are given [11, 41, 42]. As pre-
viously mentioned, morphine is the most popular
opioid in palliative medicine. Its usefulness increas-
es especially in terminal patients, given the quickly
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progressing changes in the clinical condition of the
patient. The different possibilities of administration
(oral, per rectum, intravenous, intramuscular, sub-
cutaneous, epidural, intrathecal, to brain chambers
and topical), the possibility to quickly modify the
dose and the broadest experience in its practical
application by many generations of doctors, makes
morphine an irreplaceable means of pain control in
patients at the terminal stages of their lives.
Morphine is metabolized (> 90%) mostly in the
liver to morphine-3-glucuronate (M3G) and, in small-
er quantities, to morphine-6-glucuronate (M6G) and
normorphine. All 3 metabolites are active. It is
thought that M6G in a way contributes to the anal-
gesic effect of morphine, while M3G and normor-
phine have neurostimulant properties, causing con-
vulsions and opioid hyperalgesia (paradoxical pain
after opioid administration). M3G has little or no
affinity to mi receptors and the absence of internal
activity. There is also evidence that M3G antagonis-
es analgesic activity of morphine and M6G, as well
as plays an essential part in the development of the
tolerance and hyperalgesia [43].
The rate of morphine absorption from the gas-
trointestinal tract is variable, with approx. 30–40%
bioavailability. By changing the route of adminis-
tration, different concentrations of morphine and
its metabolites in blood serum can be obtained.
Bioavailability of morphine after continuous s.c. in-
fusion is lower than its bioavailability after i.v. infu-
sion [30]. For example, after parenteral administra-
tion, normorphine is usually present in the serum
only in small quantities, but oral administration gen-
erates large quantities of this neurotoxic metabo-
lite [11].
Concentration rates after oral vs. i.v. morphine
administration are as follows [29]:
— oral morphine: M3G : M6G — 1 : 24.3 : 3.1;
— i.v. morphine : M3G : M6G — 1 : 8,5 : 1,1.
The model of central opioid activity depends on
opioid pharmacokinetics, phase of distribution de-
termined chiefly by the transport across the blood-
brain barrier, interaction with receptors and signal
transduction.
In the case of morphine, the biophase of distri-
bution is an important factor determining the on-
set of its activity, because the low lipophylicity of
morphine causes slows down the passage of the
medicine across the blood-brain barrier (84%), which
manifests itself as the phenomenon of hysteresis
concerning the relationship among the peak con-
centration of medicine in blood serum and “peak
analgesia” [44, 45].
Hysteresis can be defined as “the delay or the
lagging of the result behind its cause”. Two major
causes of the delay phase in case of morphine are:
limited access to the place of medicine activity or
slow kinetics of the receptor, with the delay lasting
even up to 34 minutes [11].
In conclusion, it is worth mentioning the increas-
ing role of intravenous administration of medicines
at the terminal stages of cancer patients’ life. In
spite of the preference for oral administration when
pain is relatively stable, quite often, especially in
the last days of the life one observes the tendency
to change opioid administration route to intrave-
nous or subcutaneous [46]. Data concerning chang-
es in opioid dosage at terminal stages of life are not
unequivocal. Some researchers advocate an escala-
tion of pain relief medicines [47], while others are in
favour of stable dosage in last seven days of life
[48]. These data conform to authors’ own unpublic
research presented at the last Congress on Pallia-
tive Medicine. MEDD in the last twenty-four hours
of  life and average MEDD of the last three and five
days were comparable.
Maier et al. conducted a retrospective survey
based on the Berlin Home Care programme includ-
ing 18% cancer patients in Berlin in 2002. Analysed
were, among others, the relationships between the
route of administration of opioid medicines and
the intensity and unpleasantness of pain in last 72
hours of the lives of patients at hospices and family
homes. The intensity of pain was rated using a 4-
grade scale. The greatest exacerbation of pain (over
50%) was most often noted with the transdermal
opioid administration route, while with repeated
subcutaneous injections they were somewhat rarer.
Continuous intravenous infusion was associated
with unsatisfactory pain control in approx. 35% cas-
es, continuous subcutaneous infusion in approx.
13% cases, and oral administration with less than
10% patients treated via this route. Similar results
were obtained when studying the relationship be-
tween the route of administration and the unpleas-
antness of pain. Most frequently, considerable un-
pleasantness accompanied the transdermal route,
followed by repeated hypodermic injections and
continuous intravenous infusions. The continuous
subcutaneous infusion and the oral route were as-
sociated with the least frequently reported stron-
gest unpleasantness of pain. The authors conclud-
ed that in the event of any problems with pain
control via transdermal opioid administration, it is
necessary to change the route of administration. In
these cases, continuous subcutaneous infusion can
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constitute the optimal method. It was also under-
scored that in a number of cases oral administra-
tion of medicines in the final days of patients’ lives
is possible and should not be changed, since it is
not only convenient, but also very effective [49].
Mercandante et al. demonstrated that despite
the rich literature and the ever broader knowledge
in the area of pain treatment, many patients suffer-
ing from moderate or even severe cancer pain still
do not receive an appropriate therapy [50]. Authors
underscore the need for education, especially in-
volving oncologists and all those who consult can-
cer patients in their own practice. It is important
not only to know the arsenal of medicines that we
have at our disposal, but also, as was demonstrat-
ed in this article, the possibility to change their ad-
ministration routes depending on the clinical condi-
tion and context of the patient. An appropriate
choice of administration route or its exchange to an
alternative one may in a number of cases improve
the comfort and quality of life of patients receiving
palliative care.
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